My research is focused on Machine Learning with applications in Bioinformatics and Health Informatics, and Data Management of the Breast Cancer Now Tissue Bank (BCNTB).
My research is focused on studying changes in metabolism and metabolic stresses that are caused by oncogene activation and how these stresses lead to tumour suppressive responses.
My research focuses on understanding the progression of early breast cancer (ductal carcinoma in situ – DCIS) to invasive disease and the role of the microenvironment in this process.
The aim of my research project is to identify and functionally characterise candidate disease genes in familial leukaemia.
I am providing bioinformatics support for several projects focusing on squamous cell carcinoma. This generally involves developing bioinformatics pipelines for large-scale cancer datasets and utilising computational approaches for analysis, with the overall aim being to uncover novel diagnostic and prognostic biomarkers.
The primary focus of my research is to establish a platform for a neo-antigens-based vaccine for triple-negative breast cancer and pancreatic cancer.
My work is currently focused on lymphoma, working on variant calling and gene expression analysis of NGS data.
My research investigates the functional relevance of RNA-binding proteins (RBPS) in normal haematopoiesis and acute myeloid leukaemia (AML) pathogenesis.
My research focuses on the use of patient-derived organoid co-cultures and genome wide CRISPR screens to unravel tumour intrinsic gene networks controlling resistance to CD3 bispecific antibodies in colorectal cancer, and possibly applicable to other tumour types.
My project is focused on investigating the role of gland phenotype in the evolution of Barrett’s oesophagus to dysplasia.
My research is focused on understanding the early stages of breast cancer by using normal human breast cells obtained through the Breast Cancer Now tissue bank as building blocks to recreate a human breast duct in the laboratory environment.
My work is based on studying signalling networks in AML primary samples in order to predict responses to kinase inhibitors.
Our research focuses on the use of modified, replicating oncolytic Vaccinia viruses and adenoviruses armed with immune-modulatory genes such as cytokines to create a self-propagating treatment for tumours that results in long-term immunological memory to the tumour cells.
My research focuses on understanding the role of RNA localisation in breast cancer progression. In particular, I am looking at how and why the cellular localization of some small nuclear RNAs (snoRNA) are altered during disease progression.
My research focuses on studying the bidirectional crosstalk between normal fibroblast (NF), CAFs, matrix organisation and the acquisition of tumour amoeboid cell state in co-culture systems.
My research aims to understand the mechanisms through which long noncoding RNAs can control genome stability in cancer.
My research focuses on novel strategies to enrich, isolate and characterise a chemo-resistant population in patients with follicular lymphoma.
My research is focused on describing the mechanisms underlying Lamin B1 nuclear disassembly in B-cell normal development and how a dis-regulated Lamin B1 removal pathway could lead to several haematological malignancies within the germinal centre in secondary lymph organs.
In 2015 I was awarded a research associate position funded by Cancer Research UK to join Dr Sanz-Moreno for my postdoc, where I develop my research studying the crosstalk between the cytoskeleton and mitochondria during tumour progression and invasion.
My work focuses on the global analysis of miRNA in pancreatic cancer and developing miRNA biomarkers for early detection of this malignancy.
My research is focused on the role of lipid metabolism in resistance to therapy in acute myeloid leukemia.
My research focuses on understanding how centrosome amplification impacts tumour angiogenesis and how this can be targeted to develop new cancer therapies.
My areas of interest are imaging biochemical processes such as metabolism/proliferation (microPET), and the use of in vivo preclinical imaging in a range of applications.
My research project is focused on understanding the impact of centrosome amplification in cancer, in particular the role of extra centrosomes in tumour evolution.
My research is focused on studying the molecular mechanisms of integrin αvβ6-driven pancreatic ductal adenocarcinoma (PDAC) progression and metastasis.
We are updating the bioinformatics data management system, expanding the analytical modules and functionalities, developing purpose-built graphical pug-ins and designing the bioinformatics infrastructure to allow the querying and analysis of data returned from projects using BCNTB tissues.
My project is focused on the identification of molecular factors affecting adenoviral therapy.
My research project aims to investigate the inflammatory cytokine IL-6 as a major target in high grade serous carcinoma, with the hope of identifying targeted therapies for treatment.
My research looks at if/how invasive traits and metabolism of amoeboid versus mesenchymal cancer cells are altered in response to tissue mechanics, with the aim of developing anti-metastasis treatment(s).
My research projects involve identifying tumour suppressors involved in regulating the hypoxic response and metabolic stress, with the aim to identify novel targeted therapies against these.
My research activity aims to characterise lncRNAs involved in the maintenance of genomic stability and to understand how their dysregulation can lead to cancer development.
My research focuses on building human tumour models within microfluidic chips that recapitulate features of the tumour microenvironment, such as blood vessels.
Our research is focused on metabolic stresses accompanying activation of oncogenes. We are investigating cell responses to metabolic stresses in order to deeply understand these mechanisms and propose metabolic targets for cancer therapies.
My research involves the conjugation and radiolabelling of antibodies, small proteins and peptides with radioisotopes followed by HPLC/TLC validation and in vitro radioligand binding assays.
We are interested in metabolic dependencies of B-cell lymphomas, in particular the serine synthesis pathway and one carbon metabolism.
My research is focused on the tumour microenvironment of ovarian cancer with a particular focus on the extracellular matrix and how current and novel treatments influence this microenvironment.
My project aims to explore the contribution of nuclear-cytoplasmic distribution and traffic of transcription factors that aid the aggressiveness of melanoma, and explore possible epigenetic aspects of melanoma initiation and progression.
My research in Prof Balkwill’s group focuses on imaging tumour-associated macrophages and other immune cells in live ex vivo tumour slices, in order to assess their behaviour and the impact of immunotherapies on the live tumour microenvironment.
My research focuses on measuring circulating tumour cells as a blood-based biomarker for aggressive prostate cancer.
My focus is on investigating the epigenetic regulation of the PI3K pathway and identifying an effective combination therapy that will disable compensatory bypass routes, overcoming drug resistance.
My research interest focuses on risk stratification signatures for Barrett’s oesophagus progression to cancer using high throughput multiplexed imaging, bioinformatics, shallow whole genome sequencing, and spatial transcriptomics.
I am interested in cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses.
My research focuses on understanding the relationship between chromosome instability mechanisms and tumour cells’ resistance to therapies.
My research will focus on studying Myosin II function during melanoma progression and its cross-talk with inflammatory and immune responses.
My research focuses on designing 3D in vitro models to understand the contribution of the tumour microenvironment during HGSOC progression.
My research project aims to integrate multi-omic molecular and histological data datasets of the microenvironment of HGSOC metastases. This work will allow us to identify key microenvironmental components and pathways that sustain and promote tumours.
My research is focused on investigating how the epitranscriptome regulates normal and malignant haematopoiesis.
My current project dissects the role that the protein FAK plays on the induction of senescence observed in endothelial cells (ECs) after DNA damage therapy, and its role in lung cancer metastasis.
My work focuses on the influence of PKN2 on the immune-microenvironment, and the invasion and metastasis of pancreatic ductal adenocarcinoma in vivo, using murine models.
My project aims to identify strategies to boost host anti-cancer immune response through enhanced oncolytic efficiency of oncolytic viruses by small molecules.
I investigate mathematical properties of somatic evolution in the context of both cancerous and healthy tissue.
My research focuses on how we can therapeutically target integrins to modulate angiogenesis in heart failure.
We are using single cell multi-omic approaches to study how cancer cell plasticity and the tumour microenvironment contribute to metastasis in colorectal cancer.
I am developing SNPnexus, a software dedicated to improving our understanding of the functional role of genetic variations to prioritise clinically relevant ones facilitating the promise of precision medicine.
My project focuses on identifying phosphorylation regulated interactions of DNA Damage repair proteins, and investigating the functional role of these interactions for DNA damage repair and cancer development.
I am investigating the role of the microenvironment on gland phenotype in the evolution of Barrett’s oesophagus to dysplasia.
My main research focuses on examining the immune landscape and identifying specific immune determinants that can predict the progression from actinic keratosis, a pre-malignant lesion, to cutaneous SCC. I am analysing single cell RNA-seq data and utilizing machine learning algorithms to evaluate potential diagnostic and prognostic markers that could aid in the identification of high-risk SCC patients. The identification of these markers is critical for early detection and intervention, which can significantly improve patient outcomes.
My research focuses on exploring why ASS1 is differently expressed in human cancers and how this information may be transferred for anticancer therapy.
My work will identify other players in the regulation of angiocrine signalling using a CRISPR screen. I will also explore the molecular mechanisms underlying how FAK controls angiocrine signalling.
My project focuses on the translation reprogramming in acute myeloid leukaemia upon stresses such as chemotherapy.
My research focuses on the perturbation of EMT-like pathways in follicular lymphoma and chronic lymphocytic leukaemia and how this promotes cancer propagation, transformation into a more aggressive form of disease and resistance to therapy.
My research project aims to identify germline mutations in families with leukaemia of unknown aetiology and study the intra and inter leukaemia heterogeneity observed in these families, through examination of clonal evolution and secondary genetic events.
The aim of my work is to develop clinically-relevant biomarkers that could aid in earlier disease detection, predict treatment response, and inform clinical management of patients.
My research is focused on understanding the role of contractility in pancreatic cancer.
Our research is focused in defining the cellular interactome of haematopoietic stem cells and leukaemic stem cells inside their niches during adulthood, ageing and disease. We are also interested in the cellular and molecular mechanisms that drive clonal selection and evolution in clonal haematopoiesis.
I am interested in understanding whether epigenetics can play a driving role in the transition from normal to transformed cells in the breast.
Using the fruit fly, Drosophila melanogaster, I aim to dissect the role played by protein phosphatases in regulating the tissue growth controlling Hippo signalling pathway, which has commonly been implicated in cancer development, progression and metastasis.
I am studying how the tumour suppressor gene LIMD1 functions in the microRNA pathway, a gene regulatory pathway that is often dysregulated in cancer.
We are using a variety of molecular and cytological techniques to study the mechanisms underlying chromosomal instability (CIN) in high grade serous ovarian cancer (HGSOC) that allow these highly adaptable tumours to become drug resistant.
My research focuses on the bioinformatic analyses of DNA methylation of circulating tumour DNA and the use of DNA methylation as a biomarker for breast cancer prognosis.
My research focuses on exploiting cell cycle vulnerabilities and signalling rewiring in tumour cells, to find new approaches to treat cancer.
My research investigates a specific composition of extracellular matrix molecules which may explain the difference between responders and non-responders to immunotherapy.
My role focuses on the design and implementation of a data management system for a pancreatic tissue bank hosted by the Institute.
My interest also lies in the development of various web-based computational analyses and data mining tools for biological research.
My research uses microscopy to examine how microtubule post-translational modifications affect DNA damage repair and how this could be exploited to enhance chemotherapy.
My project looks at the modelling of cancer for improved therapy development. I am carrying out in vivo cancer experiments, with and without modifications of the tumour microenvironment, to examine effects of such treatments on anti-cancer therapy efficacy.
My project looks at the metabolic mechanisms of drug resistance in acute myeloid leukaemia (AML). We look to understand what makes certain cells more vulnerable to AML treatment and how we can use this to improve overall treatment strategies.
My research is focused on cancer immunotherapy for pancreatic cancer, particularly immune-stimulatory molecules, armed oncolytic viruses and CAR T-cells.